1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agenus Inc. Announces Resignation of Jennifer Buell as President and Chief Operating Officer

01/06/2022 | 05:29pm EDT

Agenus Inc. announced that effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.’s President and Chief Operating Officer to become the President and Chief Executive Officer of MiNK Therapeutics Inc., a subsidiary of the Company.


© S&P Capital IQ 2022
All news about AGENUS INC.
08:31aAgenus to Participate at Jefferies Healthcare Conference
GL
08:31aAgenus Announces Virtual Annual Shareholders Meeting
GL
05/24Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance B..
GL
05/12TARGOVAX ASA : First quarter 2022 results
AQ
05/11Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 me..
AQ
05/11Targovax Announces Clinical Collaboration with Agenus for Upcoming ONCOS-102 Phase 2 Me..
CI
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
05/10TRANSCRIPT : Agenus Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10AGENUS : Q1 Earnings Snapshot
AQ
05/10Agenus Corporate Update and First Quarter 2022 Financial Report
GL
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Financials (USD)
Sales 2022 66,2 M - -
Net income 2022 -238 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,62x
Yield 2022 -
Capitalization 393 M 393 M -
Capi. / Sales 2022 5,93x
Capi. / Sales 2023 3,54x
Nbr of Employees 441
Free-Float 89,9%
Chart AGENUS INC.
Duration : Period :
Agenus Inc. Technical Analysis Chart | AGEN | US00847G7051 | MarketScreener
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,45 $
Average target price 7,50 $
Spread / Average Target 417%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Steven O’Day Chief Medical Officer
Craig Winter Chief Information Officer
Wadih Jordan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.-55.28%390
MODERNA, INC.-48.48%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-27.93%38 232
SEAGEN INC.-11.73%24 569
ICON PUBLIC LIMITED COMPANY-31.56%17 581